{"id":8005,"date":"2014-04-17T12:48:58","date_gmt":"2014-04-17T11:48:58","guid":{"rendered":"http:\/\/www.asperbio.com\/?page_id=8005"},"modified":"2019-08-27T11:31:01","modified_gmt":"2019-08-27T08:31:01","slug":"kornea-dustroofia","status":"publish","type":"page","link":"https:\/\/www.asperbio.com\/et\/asper-ophthalmics-testid\/kornea-dustroofia\/","title":{"rendered":"Kornea d\u00fcstroofia"},"content":{"rendered":"<h2 style=\"padding-left: 5px;\"><span style=\"color: #f6a703;\">Kornea d\u00fcstroofiaga seotud geenide sekveneerimine<\/span><\/h2>\n<div class=\"sm_post_content\" style=\"background: url('https:\/\/www.asperbio.com\/wp-content\/uploads\/t-oranz.png') repeat-y; padding-left: 40px;\">\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Geenid:<\/strong><\/td>\n<td><em>CHST6, COL17A1, COL5A1, COL8A2, CYP4V2, DCN, GSN, KRT3, KRT12, LOXHD1, PIKFYVE, PRDM5, SLC4A11, SOD1, ZEB1, ZNF469, TACSTD2, TGFBI, UBIAD1, VSX1<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #f6a703; background-color: #f6a703; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Metoodika:<\/strong><\/td>\n<td>Kodeeriva piirkonna sekveneerimine (NGS).<br \/>\nKoopiaarvu muutuste bioinformaatiline anal\u00fc\u00fcs (CNV). CNV leidude kinnitamine teise meetodiga toimub lisaanal\u00fc\u00fcsina, vastavalt hinnakirjale.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #f6a703; background-color: #f6a703; height: 2px; border: none; width: 100%;\" \/>\n<table style=\"width: 590px;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Testi valmimisaeg:<\/strong><\/td>\n<td>6-9 n\u00e4dalat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #f6a703; background-color: #f6a703; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>N\u00f5uded proovi-materjalile:<\/strong><\/td>\n<td>2-4 ml t\u00e4isverd antikoagulandiga EDTA (lilla korgiga katsuti)<\/p>\n<p>1\u00a0\u00b5g DNA-d elueerituna TE, AE puhvris v\u00f5i steriilses vees, kontsentratsiooniga 100-250 ng\/\u00b5l<br \/>\nDNA saata toatemperatuuril v\u00f5i k\u00fclmutatuna. A260\/A280 suhe peaks olema 1.8-2.0. DNA peab agaroosgeelis olema detekteeritav \u00fche tervikliku b\u00e4ndina.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #f6a703; background-color: #f6a703; height: 2px; border: none; width: 100%;\" \/>\n<table style=\"width: 590px;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Tellimine:<\/strong><\/td>\n<td>Proovimaterjal saata koos <span style=\"color: #f6a703;\"><strong><a style=\"color: #f6a703;\" href=\"https:\/\/www.asperbio.com\/wp-content\/uploads\/Asper-Ophthalmics-saatekiri.doc\">saatekirjaga<\/a><\/strong><\/span> Asper Biogene laborisse<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #f6a703; background-color: #f6a703; height: 2px; border: none; width: 100%;\" \/>\n<\/div>\n<p><strong>N\u00e4idustused geenitesti tegemiseks:<\/strong><\/p>\n<ol>\n<li>Kliinilise diagnoosi kinnitamine<\/li>\n<li>Kandluse m\u00e4\u00e4ramine<\/li>\n<li>Geneetiline n\u00f5ustamine<\/li>\n<\/ol>\n<p><b>Kornea d\u00fcstroofia<\/b> hulka kuulub terve rida haigusi, mis on p\u00f5hjustatud kornea mittep\u00f5letikulisest v\u00f5i mittenakkuslikust kahjustusest. Erinevad kornea d\u00fcstroofia vormid klassifitseeritakse epiteeli, strooma ja endoteeli d\u00fcstroofiateks. Haigus avaldub tavalistelt esimese 20 eluaasta jooksul. Haigust iseloomustab progresseeruv n\u00e4gemise halvenemine, millele lisandub olenevalt haiguse alat\u00fc\u00fcbist mitmesuguseid teisi s\u00fcmptomeid. Haiguse erinevate alat\u00fc\u00fcpide esinemissagedus varieerub suurtes piirides.<\/p>","protected":false},"excerpt":{"rendered":"<p>Kornea d\u00fcstroofiaga seotud geenide sekveneerimine Geenid: CHST6, COL17A1, COL5A1, COL8A2, CYP4V2, DCN, GSN, KRT3, KRT12, LOXHD1, PIKFYVE, PRDM5, SLC4A11, SOD1, ZEB1, ZNF469, TACSTD2, TGFBI, UBIAD1, VSX1 Metoodika: Kodeeriva piirkonna sekveneerimine (NGS). Koopiaarvu muutuste bioinformaatiline anal\u00fc\u00fcs (CNV). CNV leidude kinnitamine teise meetodiga toimub lisaanal\u00fc\u00fcsina, vastavalt hinnakirjale. Testi valmimisaeg: 6-9 n\u00e4dalat N\u00f5uded proovi-materjalile: 2-4 ml t\u00e4isverd antikoagulandiga [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":11406,"menu_order":7,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-8005","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/8005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/comments?post=8005"}],"version-history":[{"count":3,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/8005\/revisions"}],"predecessor-version":[{"id":24427,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/8005\/revisions\/24427"}],"up":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/11406"}],"wp:attachment":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/media?parent=8005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}